Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Apr;16 Suppl 1(0 1):10-3.
doi: 10.1111/hiv.12228.

Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

N Geffen  1 , P Aagaard, G M Corbelli, M Meulbroek, D Peavy, C Rappoport, S Schwarze, S Collins; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Community Advisory Board
Affiliations
Randomized Controlled Trial

Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

N Geffen et al. HIV Med. 2015 Apr.

Abstract

Determining when to start antiretroviral treatment (ART) is vitally important for people living with HIV. Yet the optimal point at which to start to maximize clinical benefit remains unknown. In the absence of randomized studies, current guidelines rely on conflicting observational data and expert opinion, and consequently diverge on this point. In the USA, ART is recommended irrespective of CD4 cell count. The World Health Organization now recommends starting ART at a CD4 cell count of 500 cells/μL, while the threshold for the UK and South Africa remains at 350 cells/μL. The Strategic Timing of AntiRetroviral Treatment (START) study, one of the largest clinical trials on the treatment of HIV infection, will answer this question. START compares two treatment strategies: immediate treatment at a CD4 cell count of 500 cells/μL or higher versus deferring treatment until the CD4 cell count decreases to 350 cells/μL or until AIDS develops. START includes seven substudies, five of which will clarify the relative contributions of HIV and ART in common comorbidities. START is fully enrolled and expected to be completed in 2016. HIV advocates support the study's design and have been involved from inception to enrolment. The trial will produce rigorous data on the benefits and risks of earlier treatment. It will inform policy and treatment advocacy globally, benefitting the health of HIV-positive people.

Trial registration: ClinicalTrials.gov NCT00867048.

Keywords: CD4; HIV; antiretroviral therapy; community; initiation of therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. UNAIDS. Around 10 million people living with HIV now have access to antiretroviral treatment [Internet] [cited 2014 Jun 1]; Available from: http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementa...
    1. WHO; [cited 2014 Jun 1]. WHO | Global update on HIV treatment 2013: Results, impact and opportunities [Internet] Available from: http://www.who.int/hiv/pub/progressreports/update2013/en/
    1. May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study. AIDS. 2014;28(8):1193–1202. - PMC - PubMed
    1. Dorrington RE, Bradshaw D, Laubscher R. Rapid mortality surveillance report 2012. Cape Town: South African Medical Research Council. ISBN: 978-1-920618-19-3.
    1. Babiker AG, Emery S, Fatkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials. 2013;10(1 Suppl):S5–S36. - PMC - PubMed

Publication types

Substances

Associated data